Haemonetics Co. (NYSE:HAE) is Riverwater Partners LLC’s 8th Largest Position

Riverwater Partners LLC grew its holdings in Haemonetics Co. (NYSE:HAE) by 12.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 50,379 shares of the medical instruments supplier’s stock after buying an additional 5,538 shares during the period. Haemonetics accounts for about 1.9% of Riverwater Partners LLC’s holdings, making the stock its 8th biggest holding. Riverwater Partners LLC’s holdings in Haemonetics were worth $3,934,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of HAE. Groupama Asset Managment purchased a new position in Haemonetics in the 4th quarter worth approximately $19,520,000. May Hill Capital LLC purchased a new position in Haemonetics during the fourth quarter worth approximately $1,399,000. Pictet Asset Management Holding SA boosted its stake in Haemonetics by 16.4% during the fourth quarter. Pictet Asset Management Holding SA now owns 6,963 shares of the medical instruments supplier’s stock worth $544,000 after buying an additional 979 shares during the last quarter. Norges Bank purchased a new stake in Haemonetics in the 4th quarter valued at $32,803,000. Finally, Zions Bancorporation N.A. increased its stake in shares of Haemonetics by 56.3% in the 4th quarter. Zions Bancorporation N.A. now owns 40,996 shares of the medical instruments supplier’s stock worth $3,201,000 after acquiring an additional 14,762 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on HAE. Needham & Company LLC lowered their price target on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday, February 15th. JMP Securities cut their price target on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. began coverage on Haemonetics in a report on Friday, December 6th. They issued an “overweight” rating and a $116.00 price objective on the stock. Finally, Bank of America cut Haemonetics from a “neutral” rating to an “underperform” rating and cut their target price for the stock from $95.00 to $68.00 in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $101.22.

Haemonetics Trading Down 2.3 %

HAE opened at $60.80 on Friday. Haemonetics Co. has a 52 week low of $58.80 and a 52 week high of $97.97. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35. The business has a fifty day simple moving average of $65.01 and a 200-day simple moving average of $74.27. The firm has a market cap of $3.05 billion, a P/E ratio of 23.94, a P/E/G ratio of 1.11 and a beta of 0.43.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 6th. The medical instruments supplier reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, equities analysts expect that Haemonetics Co. will post 4.55 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.